BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Recruiting now · Phase 1

Conditions studied: Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma

In brief

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.

Key facts

Study ID

NCT04162353

Run by

iCell Gene Therapeutics

People needed

12

Starts

2019-07-01

Expected to finish

2026-07-01

Last updated by the study team

2025-09-16

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed written informed consent; Patients volunteer to participate in the research
• Diagnosis is mainly based on the World Health Organization (WHO) 2008
• Patients have exhausted standard therapeutic options
• Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks
• Female must be not pregnant during the study

You may not qualify if…

• Patients declining to consent for treatment
• Prior solid organ transplantation
• Potentially curative therapy including chemotherapy or hematopoietic cell transplant
• Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents

Where it is running

• Peking University Shenzhen Hospital, China — Shenzhen, Guangdong, China (enrolling)
• Chengdu Military General Hospital — Chengdu, Sichuan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.